FDA Meeting Could Put NeOnc 's NEO100 Experimental Brain Cancer Drug on Faster Track
DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for its experimental intranasal brain cancer treatment NEO100, putting the company 's regulatory strategy in focus as it prepares for a randomized Phase 3 study.
NeOnc intends to seek FDA feedback on whether its existing clinical and nonclinical evidence could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval for recurrent or progressive IDH-mutant grade 4 astrocytoma.
The company also plans to discuss NEO100-012, a proposed multicenter, randomized, controlled Phase 3 trial comparing NEO100 against investigator 's-choice standard-of-care chemotherapy. Overall survival would serve as the primary endpoint.
Phase 2a results provide the foundation for the FDA discussion
The company 's accelerated approval ambitions follow results announced August 12, 2026, from the Phase 2a portion of its NEO100-01 study.
According to NeOnc, the study achieved a six-month progression-free survival (PFS-6) rate of 48.9%, with a 95% confidence interval of 26.3% to 68.1%. This exceeded the protocol-defined 20% historical benchmark for standard-of-care treatment, with a reported one-sided p-value of 0.0047.
The efficacy analysis included 24 patients with IDH1-mutant tumors, 21 of whom had grade 4 disease. Five patients remained on treatment at the interim database lock on June 24, 2026.
NeOnc also reported that independent central MRI assessments were used and that no treatment-related Grade 3 or higher adverse events, treatment-related serious adverse events, or discontinuations due to treatment-related adverse events had occurred.
These results offer an encouraging signal, particularly given the limited treatment options available to patients with recurrent high-grade astrocytoma.
Why the accelerated approval strategy matters
The FDA 's Accelerated Approval Program allows certain treatments for serious conditions to receive earlier approval based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit.
For cancer treatments, progression-free survival can potentially serve as an endpoint supporting regulatory consideration, depending on the disease, treatment effect and strength of the supporting evidence.
NeOnc 's NEO100-012 may be underway, with enrollment ongoing, when any potential NDA is submitted. The trial 's final overall survival analysis would then be intended to confirm clinical benefit and support conversion to traditional approval.
A separate question concerns the company 's proposed scientific bridge between published perillyl alcohol data and its proprietary intranasal NEO100 formulation.
The FDA is also expected to discuss the adequacy of the existing nonclinical safety package and whether NEO100 could qualify for Breakthrough Therapy designation.
Insider purchases add another dimension
There is also a notable corporate insider development worth considering.
In its November 5, 2026, third-quarter business update, NeOnc reported that Executive Chairman and CEO Amir Heshmatpour and Dr. Thomas C. Chen purchased a combined 160,016 shares of company common stock for approximately $629,000 in open-market transactions following the Phase 2a results. The company said the purchases were made using personal funds.
Heshmatpour has continued buying shares in the open market, purchasing 80,000 shares for approximately $269,082 across November 5, 6 and 9, according to SEC Form 4 filings. The transactions included 30,000 shares at a weighted average price of $3.167 on November 5, another 40,000 at $3.3875 on November 6, and 10,000 shares at $3.86 on November 9. The purchases were made with personal funds, and no new shares were issued by the company in connection with the transactions.
The latest purchases bring Heshmatpour 's reported 2026 open-market buying to 271,000 shares, representing approximately $1.11 million, according to NeOnc, and are worth mentioning because they occurred after the August clinical announcement and before the latest regulatory development.
Short interest points a squeeze setup
Insider buying can provide an additional indication of management confidence, particularly when executives purchase shares in the open market rather than receiving equity compensation.
Market data for October 30, 2026, showed approximately 920,631 shares sold short, representing approximately 7.03 days to cover, well above the coveted 5 days to cover threshold, and several sites are reporting even larger amounts, which could be an even more powerful force.
November and January bring important catalysts
The FDA meeting is not the company 's only upcoming milestone.
NeOnc announced in its November 5 third-quarter update that it expects to present updated NEO100 Phase 1/2a results and NEO212 Phase 1 data at the Society for Neuro-Oncology 's annual meeting on November 13, 2026.
The NEO100 presentation will include updated results from the clinical study and compassionate-use experience.
Additional information from these presentations could help investors assess whether the August topline findings remain consistent with the updated clinical dataset.
The company also has a separate regulatory milestone involving NEO212, its oral investigational drug candidate. An FDA End-of-Phase 1 Type B meeting concerning NEO212 is scheduled for November 17, 2026, according to the company 's September announcement.
For NEO100, the early January 2027 meeting will be the next major regulatory event, with the company saying it expects to provide an update after receiving and reviewing the FDA 's official meeting minutes, as the content of those minutes could be more important than the announcement that the meeting itself has been scheduled.
About 247MarketNews
In today 's fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you 're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
247MarketNews
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company 's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends, " "may, " "will, " "plans, " "expects, " "anticipates, " "projects, " "predicts, " "estimates, " "aims, " "believes, " "hopes, " "potential " or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company 's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company 's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
© 2026 GlobeNewswire, Inc. All Rights Reserved.
